BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
Portfolio Pulse from Benzinga Newsdesk
BioAtla has announced its plans for the near future, including the submission of an abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer to the IASLC 2023 North America Conference on Lung Cancer. A KOL event is planned for December 4, 2023, following the conclusion of the IASLC conference. An R&D day is planned for December 13, 2023, to discuss BA3071 (CAB-CTLA-4) Phase 1/2 basket trial. The company will also host its third quarter 2023 financial results conference call and webcast on November 7, 2023.
October 10, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioAtla's announcement of its near-term milestones, including the submission of an abstract on CAB-AXL-ADC, BA3011, and the hosting of its Q3 2023 financial results conference call, could potentially impact its stock price.
The announcement of near-term milestones, including the submission of an abstract on a potentially significant product, and the hosting of a financial results conference call, could potentially influence investor sentiment and impact the stock price of BioAtla.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100